Elamipretide
Also known as: SS-31, MTP-131, Bendavia, Forzinity
Classification
Peptide
Regulatory Status
FDA-approved prescription product (accelerated approval)
Sources
3
Review
n/a
Overview
Elamipretide is a mitochondria-targeted tetrapeptide (SS-31 class) described as associating with cardiolipin on the inner mitochondrial membrane to support bioenergetics in labeled disease contexts.
Evidence and limitations
Human/preclinical evidence breakdown is not available in this record.
Pathways
cardiolipin-associated bioenergetic support
inner mitochondrial membrane / cardiolipin-associated processes
Benefits
FDA accelerated approval of Forzinity (elamipretide) is for improving muscle strength in eligible Barth syndrome patients. This is a narrow rare-disease indication, not a general performance or anti-aging approval.
Interactions & cautions
Flagged in source data
gray-market SS-31 research vials used as if interchangeable with Forzinity
Drug interactions
other investigational mitochondrial therapies — Combined effects are not established. (review)
These are observational flags for review, not individualized instructions.
Sources
Educational reference only — not medical advice.
What people report (anecdote)
CLINICAL DATA (from trials)
Adverse events:
None recorded in our sources.
Effects measured:
Human trials: none found.
ANECDOTE
What people report: anecdote, not evidence
Loading…
Submit a claim you saw